The HMR C-terminus is required for HMR localization in proximity to centromeres and HP1a-bound chromatin. by Andrea Lukacs (3752956)

The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. by Andrea Lukacs (3752956)

HbA1c by BMI for new and previous diabetes diagnoses at start of TB treatment. by Sharon E. Cox (7243847)

Subjects:

Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcrip... by Mason A. McCool (11889842)

Incidence rate ratio (IRR) of outpatient visits between IC/BPS and non-IC/BPS individuals categorized by 3 age groups. by Kun-Lin Hsieh (11401919)

(a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automati... by Alexandra Dunnum VandeLoo (22209218)

Subjects:

The rate the bias decreases with sample duration is higher for cells with higher activity levels. by Liron Sheintuch (12078310)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Ribosomal subunit pathways are decreased in <i>Resf1</i> knockdown cells. by Megan R. Majocha (18529925)

“…<p>(A) GO Pathway analysis snapshots of various ribosomal subunit pathways that are decreased in 6DT1 <i>Resf1</i> KD cells. (B) The GO Cytosolic Ribosome pathway had many (C) small and large ribosomal proteins decreased in <i>Resf1</i> KD cells. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Excessive LF4A kinase activity shortens cilia and decreases IFT. by Yu-Yang Jiang (7036916)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”